FCOMV
ENTA icon

Foresite Capital Opportunity Management V’s Enanta Pharmaceuticals ENTA Stock Holding History

Foresite Capital Opportunity Management V’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.18M Hold
22,750
– – 3.54% 9
2022
Q2 		$1.07M Hold
22,750
– – 2.71% 9
2022
Q1 		$1.62M Buy
+22,750
New +$1.48M 2.27% 9

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Foresite Capital Opportunity Management V's ENTA Position: Q3 2022 in Review

Foresite Capital Opportunity Management V held its Enanta Pharmaceuticals (ENTA) position steady in Q3 2022 at 22,750 shares worth $1.18M. The position accounts for 3.54% of the portfolio, ranked #9.

Foresite Capital Opportunity Management V first reported a position in ENTA in Q1 2022 and has held it in 3 quarters since. The position peaked at $1.62M in Q1 2022. 160 funds tracked by Wall St. Rank hold ENTA as of Q3 2022.

  • Foresite Capital Opportunity Management V held 22,750 shares of Enanta Pharmaceuticals worth $1.18M as of Q3 2022.
  • Foresite Capital Opportunity Management V left its Enanta Pharmaceuticals share count unchanged in Q3 2022.
  • Enanta Pharmaceuticals made up 3.54% of Foresite Capital Opportunity Management V's portfolio in Q3 2022, its #9 holding.
  • Foresite Capital Opportunity Management V first reported a position in Enanta Pharmaceuticals in Q1 2022 and has held it in 3 quarters since.
  • Foresite Capital Opportunity Management V's Enanta Pharmaceuticals position peaked at $1.62M in Q1 2022.
  • 160 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2022.

Based on Foresite Capital Opportunity Management V's 13F filing for Q3 2022, filed 14 Nov 2022.